With $270M in new funds, Shankar Ra­maswamy looks be­yond Roivant in scal­ing his gene ther­a­py 'con­sol­i­dat­ed en­gine'

Shankar Ra­maswamy doesn’t in­tend to re­peat the Roivant play­book that his broth­er start­ed eight years ago. In­stead, he wants to con­sol­i­date the gene ther­a­py process …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER